on-invasive nodal staging in breast cancer with MRI Lymphography using gadofosveset; a pilot- study. - Gadofosveset in breast cancer

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 10 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•1. Patient with histopathologically confirmed invasive breast cancer about to undergo nodal staging.
•2. Tumor must be a T2 according the TNM 6-classification.
•3. Willing and able to undergo all study procedures
•4. Has personally provided written informed consent.

•1. Age <18,
•2. History of prior chemotherapy
•3. History of prior radiotherapy of the surrounding areas of the axilla.
•4. Pregnancy
•5. Contra indications for MRI such as pacemaker, aneurysm clips or severe claustrophobia.
•6. Allergy to any of the ingredients of Gadofosveset (Vasovist® /Ablavar®)
•7. Being unable to give informed consent in person
•8. Acute or chronic severe renal insufficiency (glomerular filtration rate <30
•mL/min/1.73m2).
•9. Acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

发起方

Medisch Universitair Ziekenhuis Maastricht